Phase 2 Trial of Pembrolizumab in Relapsed and Refractory Gray-Zone Lymphoma (GZL), Primary Central Nervous System Lymphoma(PCNSL), and Other Extranodal Diffuse Large B-cell Lymphomas

Trial Profile

Phase 2 Trial of Pembrolizumab in Relapsed and Refractory Gray-Zone Lymphoma (GZL), Primary Central Nervous System Lymphoma(PCNSL), and Other Extranodal Diffuse Large B-cell Lymphomas

Recruiting
Phase of Trial: Phase II

Latest Information Update: 13 Jul 2018

At a glance

  • Drugs Pembrolizumab (Primary)
  • Indications B cell lymphoma; Cutaneous B-cell lymphoma; Diffuse large B cell lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 26 Jan 2018 Planned initiation date changed from 31 Jan 2018 to 1 Feb 2018.
    • 27 Dec 2017 Planned initiation date changed from 27 Dec 2017 to 2 Jan 2018.
    • 21 Dec 2017 Planned initiation date changed from 1 Dec 2017 to 27 Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top